Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 3.09 USD -1.9%
Market Cap: 207.7m USD
Have any thoughts about
Eliem Therapeutics Inc?
Write Note

Eliem Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eliem Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Eliem Therapeutics Inc
NASDAQ:ELYM
Cash from Operating Activities
-$20.6m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Eliem Therapeutics Inc
Glance View

Market Cap
206.4m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.

ELYM Intrinsic Value
1.59 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Eliem Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-20.6m USD

Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Cash from Operating Activities amounts to -20.6m USD.

What is Eliem Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-13%

Over the last year, the Cash from Operating Activities growth was 45%. The average annual Cash from Operating Activities growth rates for Eliem Therapeutics Inc have been -13% over the past three years .

Back to Top